NR1H4 and metabolic dysfunction-associated steatotic liver disease: Additionally, obeticholic acid, a farnesoid X receptor agonist, has shown benefits in select cases [29].Treatment of comorbidities: Addressing comorbid conditions is integral to preventing the progression of liver fibrosis in NAFLD.